Compare Enbridge Inc (ENB) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Moderna, Inc. — how do they compare? Enbridge Inc trades at $46.42 (market cap $103.38B), while Moderna, Inc. trades at $219.07 (market cap $78.65B). The key difference: Enbridge Inc is the larger of the two by market cap, and Enbridge Inc pays a 6.02% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Moderna, Inc. for 59 Days on average.
| ENB | MRNA | |
|---|---|---|
Market Cap | $103.38B | $78.65B |
Volume | 3,684,305 | 37,373,437 |
Sector | Energy | Health |
52-Week High | $58.04 | $203.46 |
52-Week Low | $45.23 | $22.36 |
Typical Hold Time | 91 Days | 59 Days |
Enterprise Value | $185.39B | $74.80B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.465, up 1.25% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats and a 6% dividend yield. Revenue grew to $65.19B in 2025, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is mixed with a $61.63 price target, while recent news highlights its stable cash flow and expansion into renewables.
The outlook balances a high yield and growth projects against interest rate sensitivity and debt levels near 49% of assets. Upside exists if execution on the $41B backlog drives earnings, but macroeconomic pressures and technical weakness pose near-term risks for shareholders.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
